Abbott Laboratories filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in charter)
| (State or other Jurisdiction | (Commission File Number) | (IRS Employer | ||
| of Incorporation) | Identification No.) |
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including
area code: (
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities Registered Pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) |
Name of Each Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.07 — Submission of Matters to a Vote of Security Holders.
Abbott held its Annual Meeting of Shareholders on April 26, 2024. The following is a summary of the matters voted on at that meeting.
| (1) | The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number against, the number abstaining, and the number of broker non-votes, with respect to each of these persons, were as follows: |
| Name | Votes For | Votes Against | Abstain | Broker Non-Votes | ||||||||||||
| Robert J. Alpern, M.D. | 1,313,710,177 | 44,337,309 | 2,622,282 | 177,819,859 | ||||||||||||
| Claire Babineaux-Fontenot | 1,349,829,767 | 8,983,741 | 1,856,260 | 177,819,859 | ||||||||||||
| Sally E. Blount, Ph.D. | 1,325,092,846 | 32,959,734 | 2,617,188 | 177,819,859 | ||||||||||||
| Robert B. Ford | 1,264,303,130 | 90,184,905 | 6,181,733 | 177,819,859 | ||||||||||||
| Paola Gonzalez | 1,345,099,739 | 13,054,211 | 2,515,818 | 177,819,859 | ||||||||||||
| Michelle A. Kumbier | 1,341,455,910 | 16,651,339 | 2,562,519 | 177,819,859 | ||||||||||||
| Darren W. McDew | 1,340,191,689 | 17,894,587 | 2,583,492 | 177,819,859 | ||||||||||||
| Nancy McKinstry | 1,115,514,137 | 242,620,096 | 2,535,535 | 177,819,859 | ||||||||||||
| Michael G. O’Grady | 1,337,188,483 | 20,824,225 | 2,657,060 | 177,819,859 | ||||||||||||
| Michael F. Roman | 1,324,846,657 | 32,483,527 | 3,339,584 | 177,819,859 | ||||||||||||
| Daniel J. Starks | 1,318,741,720 | 39,288,121 | 2,639,927 | 177,819,859 | ||||||||||||
| John G. Stratton | 1,010,774,107 | 347,305,245 | 2,590,416 | 177,819,859 | ||||||||||||
| (2) | The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows: |
| For | Against | Abstain | Broker Non-Votes | |||||||||
| 1,492,386,144 | 42,865,598 | 3,237,885 | 0 | |||||||||
| (3) | The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 89.10 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows: |
| For | Against | Abstain | Broker Non-Votes | |||||||||
| 1,212,361,360 | 144,228,907 | 4,079,501 | 177,819,859 | |||||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ABBOTT LABORATORIES | ||
| Date: April 29, 2024 | By: | /s/ Philip P. Boudreau |
| Philip P. Boudreau | ||
| Senior Vice President, Finance and Chief Financial Officer | ||